Scarica l'app Stockscreener
18.36
2.28%
0.41
Dopo l'orario di chiusura:
18.32
-0.04
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$17.95
Aprire:
$17.95
Volume 24 ore:
418.59K
Relative Volume:
0.69
Capitalizzazione di mercato:
$234.79M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-1.6306
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
+7.75%
1M Prestazione:
+12.92%
6M Prestazione:
-63.08%
1 anno Prestazione:
-55.45%
Intervallo 1D:
$17.17
$18.47
Intervallo di 1 settimana:
$17.04
$19.95
Portata 52W:
$7.31
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
18.36 | 229.55M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Trend Review: Is now the right time to enter Tonix Pharmaceuticals Holding CorpEarnings Overview Report & High Return Trade Guides - baoquankhu1.vn
Aug Wrap: Is Tonix Pharmaceuticals Holding Corp forming a breakout patternJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue First (NASDAQ:TNXP) - Seeking Alpha
How (TNXP) Movements Inform Risk Allocation Models - Stock Traders Daily
Returns Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M A2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Fear: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear market2025 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Aug PostEarnings: What are Tonix Pharmaceuticals Holding Corps earnings expectationsWeekly Volume Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Analyst Downgrade: Will Tonix Pharmaceuticals Holding Corp face regulatory challengesJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Fibromyalgia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates - openPR.com
Block Trades: What is the fair value of Tonix Pharmaceuticals Holding Corp. stock now2025 Key Highlights & Reliable Intraday Trade Plans - moha.gov.vn
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockBreakout Watch & Verified Momentum Watchlists - Улправда
Take Profit: How analysts rate Tonix Pharmaceuticals Holding Corp. stock todayWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingWatch List & Stepwise Swing Trade Plans - Улправда
Can Tonix Pharmaceuticals Holding Corp. stock withstand economic slowdownJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Key Highlights & Trade Opportunity Analysis - ulpravda.ru
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
Daily News - FinancialContent
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals to meet with FDA in 2026 to advance experimental Lyme disease prevention drug - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
Drugmaker behind new fibromyalgia drug raises $20M for pipeline - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026 - Sahm
A single shot to prevent Lyme each year? Inside Tonix’s antibody plan - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):